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OBJECTIVES We conducted an international, prospective, randomized, double-blind, placebo-controlled
phase 2 trial in patients undergoing thrombolytic therapy or primary angioplasty for acute
ST-elevation myocardial infarction (MI) to investigate the effect of eniporide on infarct size
and clinical outcome.
BACKGROUND Experimental studies suggest that the activity of the Na/H exchange (NHE) plays an
important role in the unfavorable sequels of myocardial ischemia and reperfusion. Eniporide
specifically inhibits the NHE-1 isoform and has been shown to limit infarct size in
experimental models.
METHODS The primary efficacy end point was the infarct size measured by the cumulative release of
alpha-hydroxybutyrate dehydrogenase (alpha-HDBH) (area under the curve [AUC] 0 to
72 h). In stage 1, 50, 100, 150 or 200 mg eniporide given as a 10-min infusion before start
of reperfusion therapy were compared with placebo in 430 patients, and in stage 2, 100 and
150 mg eniporide were compared with placebo in 959 patients.
RESULTS In stage 1, the administration of 100 mg and 150 mg eniporide resulted in smaller infarct sizes
(mean alpha-HBDH AUC in U/ml  h, placebo: 44.2, 100 mg eniporide: 40.2, 150 mg
eniporide: 33.9), especially in the angioplasty group. In contrast, in stage 2 there was no
difference in the enzymatic infarct size between the three groups (placebo: 41.2, 100 mg
eniporide: 43.0, 150 mg eniporide: 41.5). Overall there was no effect of eniporide on clinical
outcome (death, cardiogenic shock, heart failure, life-threatening arrhythmias). However,
there was a significant reduction of the incidence of heart failure in patients reperfused late
(4 h).
CONCLUSIONS In this large study administration of the NHE-1 inhibitor eniporide, before reperfusion
therapy in patients with acute ST elevation, MI did not limit infarct size or improve clinical
outcome. (J Am Coll Cardiol 2001;38:1644–50i) © 2001 by the American College of
Cardiology
Infarct size is an important determinant of the short- and
long-term outcome after acute myocardial infarction (AMI)
(1,2). The most widely used and most effective proven
See page 1651
therapy to limit infarct size is early reperfusion induced by
thrombolytic therapy or primary angioplasty (3,4). Al-
though beneficial in terms of myocardial salvage, reperfu-
sion itself may contribute to additional damage of the
myocardium known as “reperfusion injury” (5–7). Various
experimental studies suggest that ischemia/reperfusion in-
jury is due, at least in part, to the Na/H exchange (NHE)
system (8). Myocardial ischemia or reperfusion is associated
with intracellular acidosis that leads to an activation of the
NHE, which extrudes H from cells in exchange for Na.
Since the ATP-dependent Na/K pump becomes inactive
during ischemia, NHE-mediated Na influx leads to the
intracellular accumulation of Na. This, in turn, stimulates
Ca2 influx through the Na/Ca2 exchange mechanism,
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leading to intracellular Ca2 overload, which mediates the
unfavorable sequels of myocardial ischemia and reperfusion
such as expansion of myocardial infarction (MI), myocardial
stunning and arrhythmias (9). Eniporide belongs to the new
class of drugs that specifically inhibit the NHE-1 isoform,
which is the predominant isoform in the cardiac myocytes.
Extensive preclinical studies, in vitro and in animals, have
suggested that NHE inhibition with eniporide before the
onset of ischemia is a very effective and reproducible means
of limiting the extent of infarction (10,11) and that this
agent provides protective benefit even when given just
before reperfusion (10).
The Evaluation of the Safety and Cardioprotective Ef-
fects of Eniporide in AMI (ESCAMI) study was conducted
to investigate the hypothesis that eniporide would eventu-
ally increase myocardial salvage when given as an adjunct to
reperfusion treatment of AMI.
METHODS
ESCAMI was an international, prospective, randomized,
double-blind, placebo-controlled phase II dose finding
study. All patients gave written informed consent, and the
study protocol was approved by each center’s institutional
ethics committee.
Patient selection. Patients aged between 18 and 75 years
presenting with chest pain suggesting an AMI and lasting
for at least 30 min were eligible for enrollment. The
presence of an ST-segment elevation of0.1 mV in at least
two limb leads or0.2 mV in two contiguous chest leads of
the same vascular territory on the admission electrocardio-
gram (ECG) was required for enrollment. The start of
reperfusion therapy was to be initiated within 6 h after the
start of symptoms. The decision to perform primary angio-
plasty or to treat the patient with thrombolytic therapy was
left to the discretion of the treating physician. Exclusion
criteria were prehospital thrombolysis, Killip class IV on
admission, known history of renal failure, history of severe
allergic reaction, history of autoimmune diseases, preg-
nancy, severe concurrent illness with reduced short-term
prognosis, inability to give informed consent and participa-
tion in another study within the past 30 days.
Treatment protocol. The blinded study medication was
administered with a syringe pump over 10 min in a separate
intravenous line. In patients receiving thrombolytic therapy,
the infusion had to be completed at least 15 min after the
start of treatment, while, in patients treated with primary
angioplasty, the infusion had to be completed at least
10 min before the start of percutaneous transluminal coro-
nary angioplasty (PTCA).
Study end points. The primary efficacy end point was
infarct size determined by the cumulative release of alpha-
hydroxybutyrate dehydrogenase (alpha-HBDH) (area under
the curve [AUC]: 0 to 72 h) (12). Secondary cardiac
markers, including creatine kinase (CK), CK-isoenyme
(CK-MB), troponin T and I were examined. Other second-
ary end points were clinical events occurring within the first
six weeks, in particular, death, sustained ventricular arrhyth-
mias, resuscitation from cardiac arrest, cardiogenic shock,
heart failure, major bleedings, stroke, need for revascular-
ization, recurrent ischemia, reinfarctions and rehospitaliza-
tion. In addition, an analysis of the extent of ST-segment
resolution, a marker of the actual perfusion status of the
myocardium, was done.
Trial design. The ESCAMI study employed a two-stage
adaptive design (13,14). In stage 1, four doses were consid-
ered: 50 mg, 100 mg, 150 mg and 200 mg eniporide (Merck
KGaA, Darmstadt, Germany). The objectives of stage 1
were threefold: to obtain some initial evidence of the
primary efficacy end point, to select a subset of doses to be
carried forward into stage 2 and to determine the number of
patients to be recruited for stage 2. A monotone dose-
response relation was assumed, and, thus, a one-sided linear
trend test was employed to test for efficacy at the first stage.
A one-sided formulation of the null hypothesis was adopted
to avoid conflicting directional decisions between the two
stages of the trial. The global null hypothesis was tested by
means of combining the results of tests of the individual
hypothesis. If the individual null hypothesis is tested in a
two-sided context, problems with conflicting directional
decisions could arise. Therefore, the significance level was
fixed at alpha  2.5%, one-sided. A sample size of 100
patients per group was fixed without power calculations.
For stage 2, the primary test for efficacy was again
addressed comparing the mean response for the most
effective dose selected from stage 1, the 150-mg dose group,
with placebo. In addition, 100 mg eniporide was identified
as a dose, which might also provide a clinically relevant
effect, showing a 9% enzymatic infarct size reduction in
stage 1. The one-sided t test was applied for this compar-
ison, leading to a p value, p2. The test of the global
intersection null hypothesis over both stages was to be
performed by combining the separate p values p1 and p2 by
Fisher combination test. Multiple inference on the individ-
ual dose-placebo comparisons was to be performed by
stepwise procedure based on the relation among the doses.
Abbreviations and Acronyms
alpha-HDBH  alpha-hydroxybutyrate dehydrogenase
AMI  acute myocardial infarction
AUC  area under the curve
CK  creatine kinase
CK-MB  creatine kinase isoenzyme
ESCAMI  Evaluation of the Safety and
Cardioprotective Effects of Eniporide in
Acute Myocardial Infarction study
MI  myocardial infarction
NHE  Na/H
PTCA  percutaneous transluminal coronary
angioplasty
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If p2 alpha, then the individual p values for the one-sided
comparison of 150 mg versus placebo from both stages were
to be combined by Fisher product test at full level alpha 
0.025. Since the p value for this comparison at stage 1was
considerably smaller than the overall p1 value, the proof of
principle would always prove the 150-mg dose to be
superior to placebo. Hence, if the proof of principle had
succeeded, one might immediately have proceeded to the
individual comparison of 100 mg versus placebo at full level
alpha. This, in analogy, was to be performed by combining
the two respective one-sided p values from the two stages.
In stage 1 the SD in the total sample pooled over treatments
for the primary target variable AUC of HBDH was 26.17
U/ml  h. Sample size calculation yielded a sample size of
316 patients per group to be enrolled in stage 2. With 316
patients per group in stage 2 (intention-to-treat popula-
tion), a true difference between two groups of   0.25 SDs
could be detected for the primary target variable with a
probability of 90% at alpha  0.032 significance level
(one-sided, two-sample problem, normal distribution). The
power would be 88% at alpha  0.025 significance level.
Enzyme measurement. Samples of blood for assessment of
alpha-HBDH, CK and CK-MB were collected on admis-
sion and after 4, 8, 12, 16, 24, 36, 48, 60 and 72 h. Troponin
I and T were measured every 24 h up to day 3. At the study
sites, the blood samples for the measurement of cardiac
enzymes were centrifuged (1,500 g for approximately
10 min), serum stored at 20°C and then shipped to the
central laboratory by courier (BARC, NV Bioanalytic Re-
search Corporation, Brussels, Belgium). The study protocol
predefined specific rules for handling and imputation of
missing values (14).
ECG evaluation. Twelve-lead ECGs were recorded at
baseline, at 90 (70 to 110) min and 180 (120 to 240) min
after the start of thrombolytic therapy and immediately after
PTCA (5 to 30 min) and 90 (60 to 120) min after the start
of PTCA. The sum of the ST-segment elevation was
measured by a central core laboratory as previously described
(15). Complete resolution was defined as resolution of the
initial sum of ST-segment elevation 70%. Partial resolu-
tion was defined as ST resolution 70% to 30%, while no
resolution was defined as ST resolution 30%.
RESULTS
Enrollment began in November 1998 and was completed in
March 2000. In stage 1, a total of 433 patients were enrolled
in five European countries, while in stage 2, 978 patients
were enrolled in 93 centers in 10 European countries. For
various reasons, 22 patients received no study medication;
therefore, 1,389 patients formed our study population.
Baseline characteristics were well balanced across the
treatment groups (Table 1). The mean time between start of
thrombolytic therapy and start of study medication was
1.6  9.7 min, and the mean time between start of study
medication and start of PTCA was 27  16 min. The
reperfusion therapy performed in the total study population
was primary PTCA in 38.0%, thrombolysis with mainly
streptokinase or alteplase in 61.3% (while only 0.7% did not
receive any reperfusion therapy), without any differences
between the treatment groups. In patients treated with
primary PTCA, the Thrombolysis in MI (TIMI) flow grade
before PTCA was 0/1 in 82.4%, 2 in 9.3% and 3 in 6.8%.
The intervention was successful in 91.7% of the patients;
TIMI flow grade 3 was achieved in 87.7% and a TIMI flow
grade 2 in 4.0% of the patients. There were no significant
differences with respect to TIMI flow grade before and after
PTCA between the treatment groups.
Table 1. Baseline Characteristics of the Study Population
Characteristics
Placebo
(n  410)
50 mg
(n  86)
100 mg
(n  412)
150 mg
(n  390)
200 mg
(n  91)
Age 59 61 60 60 59
Mean (range) (26–89) (39–83) (29–84) (31–79) (37–80)
Weight (kg) 80 81 80 81 80
Mean (range) (50–115) (45–125) (53–126) (54–110) (54–116)
Men/women (%) 78/22 79/21 76/24 78/22 76/24
Diabetes 69 (17%) 9 (10%) 57 (14%) 71 (18%) 18 (20%)
Hypertension 135 (33%) 34 (40%) 147 (35%) 137 (35%) 23 (25%)
Hyperlipidemia 165 (40%) 27 (31%) 161 (39%) 142 (36%) 23 (25%)
Previous AMI n (%) 49 (12%) 17 (19.8%) 67 (16.3%) 60 (15.4%) 10 (11.0%)
Anterior infarct location n (%) 165 (40.2%) 27 (31.4%) 156 (37.9%) 158 (40.5%) 34 (39.5%)
Killip class n (%):
I 370 (90.2%) 77 (89.5%) 380 (92.2%) 69 (93.2%) 86 (94.5%)
II 38 (9.3%) 8 (9.3%) 25 (6.1%) 5 (6.8%) 3 (3.3%)
III 2 (0.5%) 1 (1.2%) 7 (1.7%) 0 2 (2.2%)
Time between symptom onset and
admission (min)
141  92 145  61 135  82 143  80 140  80
Time between admission and start
of thrombolysis/PTCA (min)
45/81 47/85 49/77 50/78 46/77
AMI  acute myocardial infarction, PTCA  percutaneous transluminal coronary angioplasty.
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Cardiac enzyme release as a measure of infarct size. The
results for the cumulative release of cardiac enzymes for
stage 1 are presented in Table 2. The prespecified one-sided
linear trend test revealed a p value of 0.12 for the primary
end point alpha-HBDH AUC 0 to 72 h. Neither the 50-
nor the 200-mg dose differed from placebo, and there was
no dose-effect relationship. In the prespecified secondary
analyses, statistically significant reductions of enzyme re-
lease relative to placebo were noted for alpha-HBDH, CK
and CK-MB in the 100- and 150-mg eniporide groups.
The effect on infarct size was most striking in the patients
treated with primary PTCA (n  165); in these patients
alpha-HBDH AUC 0 to 72 h in U/ml  h was reduced
from 50.7 in the placebo group to 37.7 25.7%) and 29.6
(41.7%) in the 100- and 150-mg eniporide groups,
respectively.
Based on these results, two doses, 100 and 150 mg, were
selected for stage 2, taking into account the rules for dose
selection predefined in the study protocol (14).
The positive findings of the first stage of the trial could
not be confirmed in the second stage of the trial. In Table
3 the results are shown and did not reveal any effect of
eniporide on the primary and secondary end points. In
predefined subgroups, there was no significant reduction in
cardiac enzyme release by eniporide (Table 4). In another
subgroup of patients with anterior infarct location treated
with PTCA, no difference in the primary end point alpha-
HBDH between placebo (n 69, 50.3 33.7) and patients
treated with 100 mg (n  62, 53.6  31.2) or 150 mg (n 
54, 53.6  36.4) eniporide was observed. Also, in patients
with total occlusion before and TIMI 3 flow after PTCA,
no benefit with eniporide was seen (placebo: n 85, 44.0
29.6; 100 mg: n 78, 47.4 26.7; 150 mg: n 82, 50.8
31.9).
ST-resolution analysis. In the total study population, the
sum of ST elevations was 1.7  1 mV for anterior and
0.85  0.5 mV for inferior infarctions and did not differ
between the treatment groups. In ECG 2 and 3, there were
no differences between the placebo and the eniporide-
treated patients with respect to the distribution of the three
ST resolution groups. The rate of patients with complete
ST resolution in ECG 2 (3) was 29.3% (46.5%), 32.2%
(45.7%) and 30.7% (45.8%) in the placebo, 100-mg and
150-mg eniporide groups, respectively.
Clinical outcome and adverse events. Table 5 shows the
secondary end point data on the clinical outcome of all dose
groups. There was no difference in clinical outcome be-
tween the 100 mg, 150 mg and placebo groups; the dose
groups were evaluated in sufficient patient numbers. The
overall number of deaths was low. However, there was a
nonsignificant excess of deaths within six weeks (19 deaths
with 100 mg, 20 with 150 mg vs. 15 with placebo) and a
nonsignificant excess of stroke events in patients treated
with eniporide (seven with 150 mg, three with 100 mg and
one with placebo). The stroke events occurred in all but two
cases (one in the placebo group and one in the 150-mg
group) in patients treated with thrombolysis. Four of the
seven strokes in the 150-mg group occurred within 24 h
after eniporide treatment; the remaining occurred at day 4,
11 and 18, respectively; none of these strokes were due to
intracranial hemorrhages.
In a subgroup of patients (n  322) in whom reperfusion
was initiated more than 4 h after symptom onset, the
150-mg dose group showed a significant reduction of
patients with heart failure symptoms (Killip class II)
compared with placebo (placebo: 21.9 vs. eniporide: 11.1%,
p  0.02).
The overall tolerability of study medication with respect
to reported adverse events (hypotension, rhythm distur-
bances, laboratory abnormalities or sensory symptoms) was
Table 3. Cumulative Enzyme Release in Stage II (mean  SD).
Treatment
Group
Placebo
(n  322)
100 mg
(n  321)
150 mg
(n  316)
-HBDH AUC
(U/ml  h)
41.2  28.5 43.0  26.1 41.5  25.9
CK AUC
(U/ml  h)
63.6  50.3 69.1  50.2 68.0  56.5
CK-MB AUC
(U/ml  h)
6.5  6.9 6.9  6.2 6.6  6.7
Troponin I peak
value (ug/l)
249.1  212.8 273.2  218.0 281.0  237.1
Troponin T peak
value (ug/l)
4.1  4.0 4.4  4.0 4.3  3.5
-HBDA  alpha-hydroxybutyrate dehydrogenase; AUC  area under the curve;
CK  creative kinase; CK-MB  creative kinase isoenzyme.
Table 2. Cumulative Enzyme Release in Stage I (Mean  SD)
Treatment
Group
Placebo
(n  88)
50 mg
(n  86)
100 mg
(n  91)
150 mg
(n  74)
200 mg
(n  91)
-HBDH AUC
(U/ml  h)
44.2  26.0 45.3  31.8 40.2  22.5 33.9  20.5 43.9  27.0
CK AUC
(U/ml  h)
70.9  56.5 69.5  54.9 58.1  39.2 48.1  36.0 69.5  49.2
CK-MB AUC
(U/ml  h)
6.8  7.0 6.0  5.3 5.9  5.3 4.5  4.1 6.5  5.2
-HBDH  alpha-hydroxy butyrate dehydrogenase; AUC  area under the curve; CK  creative kinase; CK-MB  creative
kinase isoenzyme.
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good, and there were no significant differences between the
placebo and eniporide groups.
DISCUSSION
Early reperfusion has been shown to salvage myocardium
and decrease mortality in patients with evolving MI. How-
ever, reperfusion itself may induce additional cell damage.
There are several approaches to protect ischemic myocar-
dium under investigation (16). In experimental studies
(10,11,17,18) and in a small clinical trial (19), inhibition of
the NHE system has been shown to decrease infarct size
and improve left ventricular function when given before
ischemia or just before reperfusion in AMI.
Our study was the first to investigate the effects of
eniporide, a specific NHE-1 inhibitor, in a large cohort of
patients undergoing reperfusion therapy with either throm-
bolysis or primary PTCA for acute ST-elevation MI. The
principal finding of this study was that a 10-min infusion of
eniporide with doses up to 200 mg did not result in a
reduction of infarct size measured by cardiac enzyme release.
There were no subgroups of patients identified that showed
a significant reduction in enzymatic infarct size. In addition,
there was an apparent lack of clinical efficacy in terms of
adverse cardiovascular clinical outcome. Moreover, there
was a nonsignificant statistical trend towards an excess of
deaths and stroke events in patients treated with eniporide.
So far there were no hints from other clinical trials (19,20)
with NHE inhibition for an excess in mortality. Thus, the
observed trend for more deaths in patients treated with
eniporide may simply have occurred by chance. The stroke
rate in patients treated with thrombolysis and placebo was
unexpectedly low (0.2%). Since no increase in strokes was
seen in the patients treated with primary PTCA, eniporide
alone did not appear to be associated with an increased risk
for stroke.
Surrogate end points for infarct size. Although mortality
reduction has been regarded as the standard for evaluating
therapeutic efficacy of adjunctive therapies in reperfusion
for AMI, surrogate end points have been advocated for a
variety of reasons (21). The rather large sample size to
demonstrate a significant survival is relatively prohibitive for
a phase II dose-finding study. Global left ventricular ejec-
tion fraction assessed by echocardiography or angiography
has been used as a surrogate end point, but there are some
drawbacks for ejection fraction as surrogate end point.
Table 4. Cardiac Enzyme Release in Prospectively Predefined Subgroups in Stage 2
(Mean  SD)
Placebo
-HBDH AUC 0 to 72 h (U/ml  h)
100 mg
Eniporide
150 mg
Eniporide
Thrombolysis (n  590) 40.7  29.4 41.8  24.8 39.7  22.6
PTCA (n  363) 42.3  27.4 45.7  28.1 44.4  30.5
Anterior infarct (n  389) 46.9  33.0 51.8  29.8 48.7  30.7
Inferior infarct (n  513) 38.4  24.7 38.6  22.0 37.1  19.9
Complete STR (n  237) 35.2  22.7 35.1  23.1 32.4  17.6
Partial STR (n  282) 42.6  23.1 43.8  24.2 46.1  20.6
No STR (n  232) 53.1  35.2 54.1  27.2 53.4  29.0
Early reperfusion (n  696) 39.8  27.3 43.2  26.6 42.5  25.6
Late reperfusion (n  229) 47.4  32.9 44.7  25.4 40.1  27.1
-HBDH  alpha-hydroxybutyrate dehydrogenase; AUC  area under the curve; early/late reperfusion  time from onset of
symptoms and start of reperfusion therapy 4 h/4 h; no, partial and complete STR  ST resolution at ECG 2.
Table 5. Clinical Events Until 42 Days and Six-Month Mortality in Stages I and II Combined
Clinical Event
Placebo
(n  410)
50 mg
(n  86)
100 mg
(n  412)
150 mg
(n  390)
200 mg
(n  91)
Death 15 (3.7%) 6 (6.9%) 19 (4.6%) 20 (5.1%) 8 (8.8%)
Cardiogenic shock 13 (3.2%) 5 (5.8%) 8 (1.9%) 11 (2.8%) 6 (6.6%)
Reinfarction 18 (4.4%) 4 (4.7%) 13 (3.2%) 15 (3.8%) 7 (7.6%)
Need for revascularization 70 (17.1%) 10 (11.6%) 77 (18.6%) 81 (20.7%) 18 (19.8%)
Sustained ventricular arrhythmia* 22 (5.4%) 5 (5.8%) 18 (4.4%) 18 (4.6%) 2 (2.2%)
Heart failure (Killip class  II) 77 (18.8%) 8 (9.3%) 53 (12.9%) 59 (15.1%) 12 (13.2%)
Stroke 1 (0.2%) 0 3 (0.7%) 7 (1.8%) 2 (2.2%)
Combined end point† 100 (24.4%) 16 (18.6%) 82 (19.9%) 87 (22.3%) 21 (23.1%)
Death, six-month 18 (4.4%) 6 (6.9%) 25 (6.1%) 29 (7.4%) 11 (12.1%)
*Defined as the occurrence of sustained ventricular arrhythmia necessitating cardioversion or defibrillation; †combined clinical end point consisting of death, cardiogenic shock,
heart failure and sustained ventricular arrythmia.
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Angiography is an invasive procedure, is costly and is not
universally available, and echocardiography has a limited
technical feasibility in up to 30% of patients. Nuclear
techniques are valuable to detect protective effects on the
myocardium in AMI patients but are available only in a
limited number of highly specialized centers. Therefore, we
have chosen enzymatic infarct size as a surrogate end point
(22). Cumulated alpha-HBDH release has gained clinical
importance for the noninvasive estimation of infarct size
because excellent correlations have been reported with
anatomic infarct sizes. Due to slow elimination, alpha-
HBDH seems to be superior to CK-MB in the estimation
of the infarct size of patients with reperfusion therapy (12).
Causes for the lack of benefit of NHE inhibition.
Various hypotheses can be proposed to explain the negative
results of this study. The regimen adopted in our trial was
chosen according to phase 1 studies to provide the highest
tolerated dose administered as fast as possible at the time of
reperfusion (23). The aim to administer the drug before
reperfusion was achieved in patients treated with PTCA
and thrombolytic therapy. Plasma levels of more than 3,500
ng/ml were observed within 10 min after the start of
eniporide. The half-life of eniporide of approximately 2 h
ensured therapeutic plasma levels of above 1,000 ng/ml even
after more than 2 h (data not shown). Some of the patients
treated with thrombolytic therapy might have already had
recanalized vessels before the start of NHE therapy, and, in
these patients, the therapeutic effect might be only minor.
Still, simple technical reasons do not appear to have influ-
enced the negative findings significantly.
Reperfusion injury and NHE inhibition. Although the
phenomena of reperfusion injury are well recognized in
experimental models of myocardial ischemia and reperfu-
sion, the clinical relevance of it is not known. Thus, it may
well be that reperfusion injury in the clinical setting of
reperfused AMI gives no major contribution to the evolu-
tion from ischemic myocardium to myocardial necrosis (24).
However, despite evidence that the NHE mechanism is
active during early reperfusion and may contribute to
reperfusion injury, there is only equivocal evidence from
experimental studies that NHE inhibitors can protect the
myocardium when they are given after coronary occlusion or
immediately before reperfusion (8). In a recent experimental
study, cell injury was attenuated predominantly when the
NHE inhibitor cariporide was given before or during
ischemia, while there was no effect when treatment was
initiated at onset of reperfusion (25). These experimental
findings may explain the lack of efficacy of NHE inhibition
in our study. Our results do not rule out a potential benefit
of NHE inhibition when given before ischemia. In a large
trial with cariporide, another NHE exchange inhibitor,
there was a significant clinical benefit in patients undergoing
high-risk bypass surgery (20).
Our results are contrary to the findings of a small clinical
trial in a highly selected group of patients with a first
anterior MI who were randomized to receive placebo (n 
51) or cariporide (n  49) immediately before reperfusion
by primary PTCA (19). Significant improvements in wall
motion abnormalities and a borderline significant decrease
in cardiac enzyme release during the next three days were
observed in the patients treated with cariporide. It is well
recognized that measurements of infarct size are somewhat
problematic for small clinical trials due to the very high
variability of infarct size, and the numerous variables that
are known to contribute to infarct size such as time to
reperfusion, actual territory supplied by the infarct vessel,
changes in coronary perfusion pressure and collateral blood
flow are problematic as well. Particularly in small trials,
these uncontrolled factors constitute a considerable risk of
apparent imbalances in baseline myocardium at risk in the
different treatment groups. Therefore, the positive findings
of the trial with cariporide and of stage 1 of our trial might
be due to chance and to the small number of patients
studied, since, in the larger stage 2 of our study, no effect
was seen, even in the cohort of patients with anterior MI
treated with primary PTCA.
An interesting observation of the ESCAMI trial is that a
subgroup of patients being reperfused late (4 h after onset
of chest pain) seemed to have a slight benefit from adjunc-
tive eniporide in respect to enzyme release and clinical
outcome, most notably in the occurrence of heart failure
within one week after AMI. From this observation, one
might conclude that inhibition of the cardiac myocyte
NHE-1 may only be of clinical relevance if the ischemic
burden has already been present for a certain period of time
or that NHE-1 inhibition may have other, not yet recog-
nized, effects besides infarct size reduction. However, since
the subgroup of late reperfused patients was rather small in
our trial, this finding should be further substantiated in
prospectively designed clinical trials before definite conclu-
sions can be drawn.
Conclusions. In conclusion, the ESCAMI trial failed to
meet its primary objective to demonstrate a reduction in
enzymatic infarct size and an improvement in clinical
outcome in patients with ST-elevation AMI treated with
adjunctive eniporide before primary PTCA or thrombolytic
therapy.
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at www.cardiosource.com
PARTICIPATING CENTERS
Netherlands (404 patients): H. Suryapranata (Ziekenhuis
De Weezenlanden, Zwolle), L.M. van Wijk (Stichting
Chr. Ziekenhuis “Refaja”, Stadskanaal), A.E.R. Arnold
(Medisch Centrum Alkmaar), A.C. Tans (Het Nieuwe
Spittaal, Zutphen), R.W. Breedveld (Medisch Centrum
Leeuwarden Zuid), T.T. van Loenhout (Ziekenhuis
Gelderse Vallei, Bennekom), J.G.M. Tans (Stichting Gem-
ini Ziekenhuis, den Helder), J.L. Posma (Martini zieken-
huis Loc. Van Ketwich, Loc. Van Swieten, Groningen),
G.C.M. Linssen (Twenteborg Ziekenhuis, Almelo), E.D.
de Muinck (Academisch Ziekenhuis Maastricht).
France (234 patients): J.P. Monassier (Hopital Emile
Muller-Mulhouse), G. Amat (CHG-Vichy), P. Assemann
(C.H.R.U. de Lille Hopital Cardiologique-Lille), M. Ben-
acerraf (Centre Cardiologique du Nord-Saint-Denis), J.M.
Boulenc (Clinique Saint-Joseph-Colmar), C. Boureux
(Centre Hospitalier-Perpignan), S. Cheggour (Centre Hos-
pitalier de la Durance-Avignon), M. Galinier (Centre
Hospitalier Rangueil-Toulouse), K. Isaaz (C.H.R.U. de
Saint Etienne-Hopital Nord-Saint-Etienne), K. Kahlife´
(Centre Hospitalier Re´gional Bon Secours-Metz), T.
Lefevre (Institut Hospitalier Jacques Cartier-Massy), S.
Levy (Hopital Nord-Marseille), C. Loubeyre (Hopital
Claude Galien-Quincy Sous Senart), V. Lucke (C.H.G.
Hopital de Girac-Angouleˆme), M.C. Morice (Clinique du
Bois de Verrie`res Angioth.-Antony), J.C. Quiret
(C.H.R.U. d’Amiens-Hopital Sud-Amiens), P. Couppie
(Centre Hospitalier d’Haguenau-Haguenau), F. Duclos
(CHR Hopital de la Source-Orle´ans).
Germany (197 patients): U. Zeymer (Klinikum Kassel),
H. Darius (Johannes-Gutenberg-Universita¨t Mainz), G. Nau-
mann (Klinikum Su¨dstadt, Rostock), K. Machill (Med. Klini-
kum Schwerin), R. Zotz (Herzzentrum Leipzig), O. Goeing
(Krankenhaus Lichtenberg, Berlin), H. Klein (Sta¨dt. Kranken-
stalten GmbH Idar-Oberstein), S. Sen (Sta¨dt. Kliniken
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Frankfurt/M.-Hoechst), G. Berg (Univ.-Kliniken im Landes-
krankenhaus Homburg), T. Thieme (Unfallkrankenhaus
Berlin-Marzahn), S. Holmer (Klinikum der Universita¨t Re-
gensburg), J. Placke (Universita¨t Rostock), R. Zahn (Klinikum
der Stadt Ludwigshafen am Rhein).
Poland (169 patients): G. Opolski (C.S.K.A.M.,
Warszawa), J. Go´rski (Baltycka Fundacja Kardiologii,
Gdynia), W.J. Musial (Klinika Kardiologii A.M.), M. Trusz-
Gluza (Silesian Heart Centre, Katowice), T. Widomska-
Czekajska (A.M., Lublin), M. Wierzchowiecki (A.M.,
Poznan), D. Wojciechowski (Szpital Wolski, Warszawa), K.
Wrabec (Wojewo´dzki Szpital Specjalistyczny, Wroclaw), H.
Wysocki (Instytut Choro´b Wewnetrznych, Poznan), J. Kuch
(Wojewo´dzki Szpital Bro´dnowski, Warszawa), W. Pluta
(Wojewo´dzkie Centrum Medyczne, Opole).
United Kingdom (161 patients): J. Davies (Royal Gwent
Hospital), Prof. R. Wilcox (University Hospital Nottingham),
J. Dhawan (Scunthorpe General), R.M. Boyle (York District
Hospital), J.E.F. Pohl (Leicester General Hospital), N. Naqvi
(Royal Albert Edward Infirmary), W. Pugsley (Royal Sussex
County Hospital), J. Stephens (Oldchurch Hospital), R. Ol-
iver (Ipswich Hospital), F. Dunn (Stobhill Hospital), W.
Rhoden (Barnsley District General), G. Ambepitiya (St. Mar-
garet’s Hospital), P. McIntyre (Royal Alexandra Hospital), M.
Marber (St. Thomas’ Hospital London), M.R. Cowie (Aber-
deen Royal Infirmary, Foresterhill, Aberdeen).
Sweden (111 patients): G. Rasmanis (Huddinge Sjukhus,
Stockholm), S. Bandh (Centrallasarettet, Va¨steras), L.
Hagstro¨m (Falu Lasarett, Falun), O. Hansen (Univer-
sitetssjukhuset MAS, Malmo¨), J. Perk (Oskarshamns
sjukhus, Oskarshamn), L. Lundkvist (Hudiksvalls sjukhus,
Hudiksvall), B.H. Mo¨ller (La¨nssjukhuset, Sundsvall), F.
Huhtasaari (Sunderby Sjukhus, Lulea).
Belgium (92 patients): W. Van Mieghem (Z.O.L. Cam-
pus Sint Jan, Genk), Y. Taeymans (Universitair Ziekenhuis,
Gent), G. Heyndrickx (O.L.V. Ziekenhuis, Aalst), J. Bo-
land (Hoˆpital de la Citadelle, Liege`), F. Van den Branden
(Alg. Ziekenhuis Middelheim, Antwerpen), D. Mertens
(Sint Franciskus Ziekenhuis, Heusden-Zolden), E. Van der
Stichele (AZ Sint Jan, Brugge), R. Geukens (Virga Jesse
Ziekenhuis, Hasselt).
Spain (27 patients): E. Lo´pez de Sa (Hospital Gregorio
Marano´n), L. Martı´n Jadraque (Hospital Universitario La
Paz), A´. Alonso (Clı´nica Puerta de Hierro), J. Figueras
(Hospital Gene´ral Vall d’Hebron), J. L. Lo´pez-Sendo´n
(Hospital Gregorio Marano´n).
Finland (14 patients): J. Rummukainen (Savonlinna Cen-
tral Hospital, Savonlinna), L. Ha¨ma¨la¨inen (North Carelia
Central Hospital, Joensuu), T. Raasakka (Lappi Central
Hospital, Rovaniemi).
Austria (12 patients): H. D. Glogar (Universita¨tsklinik fu¨r
Innere Medizin II, Wien), R. Karnik (Krankenhaus Wien
Rudolfstiftung).
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